| Literature DB >> 34206443 |
Mohammad Ashiqur Rahman Bhuiyan Shovo1, Marzia Rahman Tona1, Jannatul Mouah1, Fayza Islam2, Md Helal Uddin Chowdhury3, Tuhin Das4, Arkajyoti Paul5, Duygu Ağagündüz6, Md Masudur Rahman1, Talha Bin Emran5, Raffaele Capasso7, Jesus Simal-Gandara8.
Abstract
Molineria capitulata is an ornamental plant that has traditionally been used to treat several chronic diseases. The present study was designed to examine the antioxidant, cytotoxic, thrombolytic, anti-inflammatory, and analgesic activities of a methanolic extract of M. capitulata leaves (MEMC) using both experimental and computational models. Previously established protocols were used to perform qualitative and quantitative phytochemical screening in MEMC. A computational study, including molecular docking and ADME/T analyses, was performed. The quantitative phytochemical analysis revealed the total phenolic and flavonoid contents as 148.67 and 24 mg/g, respectively. Antioxidant activity was assessed by examining the reducing power of MEMC, resulting in absorbance of 1.87 at 400 µg/mL, demonstrating a strong reduction capacity. The extract exhibited significant protection against blood clotting and showed the highest protein denaturation inhibition at 500 µg/mL. In both the acetic acid-induced writhing and formalin-induced paw-licking models, MEMC resulted in significant potential pain inhibition in mice. In the computational analysis, 4-hydroxybenzaldehyde, orcinol glucoside, curcapital, crassifogenin C, and 2,6-dimethoxy-benzoic acid displayed a strong predictive binding affinity against the respective receptors. These findings indicated that M. capitulata possesses significant pharmacological activities to an extent supported by computational studies.Entities:
Keywords: Molineria capitulata; anti-inflammatory; antioxidant; bioactive molecules; biological activity; computational study; medicinal plants; thrombolytic
Mesh:
Substances:
Year: 2021 PMID: 34206443 PMCID: PMC8929091 DOI: 10.3390/cimb43020035
Source DB: PubMed Journal: Curr Issues Mol Biol ISSN: 1467-3037 Impact factor: 2.976
Result of preliminary phytochemical analysis of methanol leaf extract of Molineria capitulata (MEMC).
| Phytochemicals | MEMC |
|---|---|
| Alkaloids | + |
| Carbohydrates | + |
| Flavonoids | + |
| Phenols | + |
| Tannins | + |
| Saponins | − |
| Reducing sugar | + |
| Steroids | − |
| Glycosides | + |
| Terpenoids | + |
(+) = present, and (−) = absent.
Total phenolic and flavonoid contents of methanol leaf extract of Molineria capitulata (MEMC).
| Tested Extract | Total Phenol Content | Total Flavonoid Content |
|---|---|---|
| MEMC | 148.67 ± 1.15 | 24.00 ± 0.00 |
Each value in the table is expressed as mean ± SEM (n = 3). GAE, gallic acid equivalent; QE, quercetin equivalent.
Figure 1Reducing power capacity of MEMC compared with the reference standard ascorbic acid. MEMC, methanol leaf extract of Molineria capitulata.
Figure 2Determination of LC50 value of MEMC and VS (vincristine sulfate) from linear correlation between concentrations versus percentage of mortality. Values are expressed as mean ± SEM (n = 3) where data were analyzed by two-way ANOVA (Sidak’s multiple comparison test) and *** p value less than 0.001 is considered as statistically significant. MEMC, methanol leaf extract of Molineria capitulata.
Figure 3Thrombolytic activity of MEMC (methanol leaf extract of Molineria capitulata). Percentage of clot lysis of MEMC in comparison with negative control (water). Values are expressed as mean ± SEM for 10 volunteers, where data were analyzed by Dunnett’s test and *** p value less than 0.001 is considered as statistically significant.
Figure 4Anti-inflammatory activity of MEMC (methanol leaf extract of Molineria capitulata). Percentage of inhibition of protein denaturation of MEMC in comparison with reference standard (Diclofenac Na). Values are expressed as mean ± SEM (n = 3) where data were analyzed by Sidak’s multiple comparison test and *** p value less than 0.001 is considered as statistically significant.
Analgesic effect of MEMC in acetic acid induced writhing test in mice.
| Groups | Treatment | Dose (mg/kg) | Number of Writhing | Inhibition (%) |
|---|---|---|---|---|
| Control | 1% Tween-80 | 0.1 | 61.4 ± 0.66 | - |
| Positive Control | Diclofenac-Na | 10 | 20.8 ± 0.75 *** | 66.12 |
| Plant Extract | MEMC | 400 | 27.4 ± 0.9 *** | 55.3 |
| MEMC | 200 | 46.4 ± 1.3 *** | 24.4 |
Values are presented as mean ± SEM (n = 5). *** p < 0.001 compared with the control group (Dunnett’s test). MEMC, methanol leaf extract of Molineria capitulata.
Analgesic effect of MEMC in formalin induced paw licking test in mice.
| Treatment (mg/kg) | Licking Time (sec) (Mean ± SEM) | |||
|---|---|---|---|---|
| Early Phase (0–5 min) | Inhibition (%) | Late Phase (15–30 min) | Inhibition (%) | |
| Control (0.1 mL/mouse) | 30.60 ± 5.3 | - | 44.44 ± 0.65 | - |
| Diclofenac-Na (10) | 17.40 ± 0.35 *** | 75.69 | 16.80 ± 0.75 *** | 62.16 |
| MEMC (400) | 34.60 ± 0.68 *** | 51.67 | 20.60 ± 0.87 *** | 53.60 |
| MEMC (200) | 56.00 ± 07.8 *** | 21.78 | 33.60 ± 1.55 *** | 24.32 |
Values are presented as mean ± SEM (n = 5). *** p < 0.001 compared with the control group (Dunnett’s test). MEMC, methanol leaf extract of Molineria capitulate; SEM, Standard Error Mean.
ADME property prediction for the major selected bioactive compounds of M. capitulata, obtained using Swiss ADME online tool [17].
| Compounds | MW 1 | HBA 2 | HBD 3 | Log P 4 | MR 5 | Rule of Five 6 |
|---|---|---|---|---|---|---|
| 3-(4-hydroxy-3-methoxyphenyl)acrylaldehyde | 178.18 | 3 | 1 | 1.56 | 50.06 | 0 |
| 4-hydroxybenzaldehyde | 122.12 | 2 | 1 | 1.17 | 33.85 | 0 |
| Orcinol glucoside | 286.28 | 7 | 5 | −0.47 | 67.58 | 0 |
| Pilosidine | 478.45 | 11 | 7 | −0.10 | 114.99 | 2 |
| Capituloside | 478.45 | 11 | 7 | −0.10 | 114.99 | 2 |
| Curcapital | 310.26 | 6 | 4 | 1.97 | 84.71 | 0 |
| Crassifogenin C | 348.30 | 8 | 6 | 0.54 | 84.81 | 1 |
| Breviscaside A | 480.46 | 11 | 8 | −0.10 | 115.61 | 2 |
| Methyl-4-O-coumaroylquinate | 352.34 | 8 | 4 | 0.42 | 85.80 | 0 |
| 2,6-dimeyhoxy-benzoic acid | 182.17 | 4 | 1 | 1.18 | 46.39 | 0 |
1 MW: Molecular weight-(acceptable range: <500 g/mol); 2 Hydrogen bond acceptor (HBA)-(Acceptable range: ≤10); 3 Hydrogen bond donor (HBD) (Acceptable range: ≤5); 4 Lipophilicity (Log Po/w) (acceptable range < 5); 5 Molar refractivity (MR) should be between 40 and 130. 6 Rule of five: Number of violations of Lipinski’s rule of five: accepted range: 0–4.
Toxicological property predications of the major selected bioactive compounds of M. capitulata using admetSAR online server.
| Compounds | Parameters | |
|---|---|---|
| AMES Toxicity | Carcinogens | |
| 3-(4-hydroxy-3-methoxyphenyl)acrylaldehyde | Non AMES toxic | Non-Carcinogens |
| 4-hydroxybenzaldehyde | Non AMES toxic | Non-Carcinogens |
| Orcinol glucoside | AMES toxic | Non-Carcinogens |
| Pilosidine | Non AMES toxic | Non-Carcinogens |
| Capituloside | Non AMES toxic | Non-Carcinogens |
| Curcapital | AMES toxic | Non-Carcinogens |
| Crassifogenin C | Non AMES toxic | Non-Carcinogens |
| Breviscaside A | Non AMES toxic | Non-Carcinogens |
| Methyl-4-O-coumaroylquinate | Non AMES toxic | Non-Carcinogens |
| 2,6-dimeyhoxy-benzoic acid | Non AMES toxic | Non-Carcinogens |
Docking scores of the major selected bioactive compounds of M. capitulata.
| Compounds | Docking Scores (kcal/mol) | |||
|---|---|---|---|---|
| 1HD2 | 1A5H | 20YE | 6COX | |
| 3-(4-hydroxy-3-methoxyphenyl)acrylaldehyde | - | −2.02 | −5.19 | −6.26 |
| 4-hydroxybenzaldehyde | −5.25 | −6.00 | −5.41 | −7.46 |
| Orcinol glucoside | −3.54 | −6.55 | −4.16 | −5.27 |
| Pilosidine | −3.27 | −3.95 | −4.44 | - |
| Capituloside | −3.27 | −3.96 | −4.69 | - |
| Curcapital | −4.26 | −5.86 | −5.32 | −9.32 |
| Crassifogenin C | −2.86 | −4.61 | −4.86 | −8.20 |
| Breviscaside A | −2.69 | −4.29 | −5.25 | - |
| Methyl-4-O-coumaroylquinate | −4.59 | −4.75 | −3.87 | −5.91 |
| 2,6-dimeyhoxy-benzoic acid | −3.69 | −5.62 | −5.92 | −7.11 |
| Standard drug (Ascorbic acid/Streptikinsae/Diclofenac-Na) | −5.13 | −4.53 | −4.59 | −7.26 |
Figure 5Best ranked pose of the best compound of M. capitulata. 4-hydroxybenzaldehyde and standard drug (ascorbic acid) in the binding pocket of human peroxiredoxin 5 (PDB ID: 1HD2) for antioxidant activity.
Figure 6Best ranked pose of the major compounds of M. capitulata. Orcinol glucoside and standard drug (streptokinase) in the binding pocket of human tissue-type plasminogen activator (PDB ID: 1A5H) for thrombolytic activity.
Figure 7Best ranked pose of the major compounds of M. capitulata. 2,6-dimeyhoxy-benzoic acid and standard drug (diclofenac sodium) in the binding pocket of COX-1 enzyme (PDB ID: 2OYE) for analgesic and anti-inflammatory activities.
Figure 8Best ranked pose of the major compounds of M. capitulata. 4-hydroxybenzaldehyde and standard drug (diclofenac sodium) in the binding pocket of COX-2 enzyme (PDB ID: 6COX) for analgesic and anti-inflammatory activities.
Figure 9Chemical structures of the compounds used for molecular docking study.